Initiator Pharma A/S has been approved for listing on the Nasdaq First North Growth Market
Initiator Pharma A/S (“Initiator” or “the Company”) has today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021.
Nasdaq Stockholm today announced that Initiator Pharma meets the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021. Initiator Pharma's share is currently listed on Spotlight Stock Market, with the last day of trading being October 22, 2021.
Initiator Pharma's share will continue to be traded with ISIN DK0060775872 and ticker INIT. Shareholders in Initiator Pharma does not have to take any action with regards to the change of listing venue.
In connection with the listing on Nasdaq First North Growth Market, Initiator Pharma has appointed Redeye AB as the Company's Certified Adviser. In connection with the list change, DLA Piper Denmark and DLA Piper Sweden has acted as the Company’s legal advisor.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 E-mail: [email protected]
The information was submitted for publication, through the agency of the contact person set out above on 22 October 2021 at 13:00.
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma is listed on Spotlight Stockmarket (ticker: INIT).
Read more on www.initiatorpharma.com.
